Tag: @McGovernMed

Orforglipron Shows Significant Weight Loss and Safety Benefits in Adults 65 and Older, New Analysis Finds

A sub-group analysis of the ATTAIN-1 and ATTAIN-2 trials finds that orforglipron produced significant reductions in body weight and HbA1c in adults aged 65 and older, with a safety profile consistent with younger populations.

WeightControl.com Interview with:
Deborah B. Horn, DO, MPH, FOMA
Medical Director for Center of Obesity Medicine and Metabolic Performance
McGovern Medical School
UTHealth Houston, Texas

A new sub-group analysis of two major clinical trials examines how the oral GLP-1 medication orforglipron performs in adults aged 65 and older — with encouraging findings on both efficacy and safety. Continue reading “Orforglipron Shows Significant Weight Loss and Safety Benefits in Adults 65 and Older, New Analysis Finds”